Onabotulinumtoxina in migraine: A review of the literature and factors associated with efficacy

Research output: Contribution to journalReview ArticleResearchpeer-review

13 Citations (Scopus)


The efficacy of onabotulinumtoxinA (OnaB-A) as a preventative treatment for chronic migraine, emerging fortuitously from clinical observation is now supported by class one evidence and over two decades of real-world clinical data. There is still limited ability to predict a clinically meaningful response to OnaB-A for individual patients, however. This review summarises briefly the proposed mechanism of OnaB-A in chronic migraine, the literature of predictors of clinical response, and recent developments in the field.

Original languageEnglish
Article number2898
Number of pages13
JournalJournal of Clinical Medicine
Issue number13
Publication statusPublished - 1 Jul 2021


  • Botulinum toxin
  • Migraine
  • Predictors of efficacy

Cite this